Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 638129, 12 pages
http://dx.doi.org/10.1155/2015/638129
Research Article

The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation

1Department for Internal Medicine 3, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Ulmenweg 18, 91054 Erlangen, Germany
2Institute of Cell Biology, National Academy of Sciences of Ukraine, Drahomanov Street 14/16, Lviv 79005, Ukraine
3Department of Otorhinolaryngology, Head and Neck Surgery, Section for Experimental Oncology and Nanomedicine (SEON), University Hospital, Waldstraße 1/Glückstraße 10, 91054 Erlangen, Germany
4Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
5Paediatric Immunology and Rheumatology, Children’s Hospital Brescia, Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
6Department of Biology, Institute of Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erwin-Rommel Str. 3, 91058 Erlangen, Germany

Received 11 February 2015; Accepted 12 May 2015

Academic Editor: Kurt Blaser

Copyright © 2015 Christoph Fickentscher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. W. A. Wilson, A. E. Gharavi, T. Koike et al., “International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop,” Arthritis and Rheumatism, vol. 42, no. 7, pp. 1309–1311, 1999. View at Google Scholar · View at Scopus
  3. P. G. de Groot and R. T. Urbanus, “The significance of autoantibodies against beta2-glycoprotein I,” Blood, vol. 120, no. 2, pp. 266–274, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Nalli, S. Piantoni, L. Andreoli, M. Motta, and A. Tincani, “Antiphospholipid syndrome and antiphospholipid antibodies in children: the two sides of the coin,” Israel Medical Association Journal, vol. 14, no. 5, pp. 310–312, 2012. View at Google Scholar · View at Scopus
  5. I. Schousboe, “β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway,” Blood, vol. 66, no. 5, pp. 1086–1091, 1985. View at Google Scholar · View at Scopus
  6. J. George, M. Blank, Y. Levy et al., “Differential effects of anti-β2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome,” Circulation, vol. 97, no. 9, pp. 900–906, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Willis and S. S. Pierangeli, “Anti-β2-glycoprotein I antibodies,” Annals of the New York Academy of Sciences, vol. 1285, no. 1, pp. 44–58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Fischer, J. Rauch, and J. S. Levine, “The antiphospholipid syndrome,” Seminars in Nephrology, vol. 27, no. 1, pp. 35–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Amital, M. Govoni, R. Maya et al., “Role of infectious agents in systemic rheumatic diseases,” Clinical and Experimental Rheumatology, vol. 26, no. 1, supplement 48, pp. S27–S32, 2008. View at Google Scholar
  10. T. Avčin, “Antiphospholipid syndrome in children,” Current Opinion in Rheumatology, vol. 20, no. 5, pp. 595–600, 2008. View at Publisher · View at Google Scholar
  11. M. García-Carrasco, C. Galarza-Maldonado, C. Mendoza-Pinto, R. O. Escarcega, and R. Cervera, “Infections and the antiphospholipid syndrome,” Clinical Reviews in Allergy & Immunology, vol. 36, no. 2-3, pp. 104–108, 2009. View at Publisher · View at Google Scholar
  12. P. Cruz-Tapias, M. Blank, J.-M. Anaya, and Y. Shoenfeld, “Infections and vaccines in the etiology of antiphospholipid syndrome,” Current Opinion in Rheumatology, vol. 24, no. 4, pp. 389–393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. von Landenberg, Y. Döring, S. Modrow, and K. J. Lackner, “Are antiphospholipid antibodies an essential requirement for an effective immune response to infections?” Annals of the New York Academy of Sciences, vol. 1108, pp. 578–583, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Blank, I. Krause, M. Fridkin et al., “Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome,” Journal of Clinical Investigation, vol. 109, no. 6, pp. 797–804, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Shoenfeld, M. Blank, R. Cervera, J. Font, E. Raschi, and P.-L. Meroni, “Infectious origin of the antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 65, no. 1, pp. 2–6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. E. Gharavi, S. S. Pierangeli, R. G. Espinola, X. Liu, M. Colden-Stanfield, and E. N. Harris, “Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo,” Arthritis and Rheumatism, vol. 46, no. 2, pp. 545–552, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Motta, G. Chirico, C. B. Rebaioli et al., “Anticardiolipin and anti-beta2 glycoprotein I antibodies in infants born to mothers with antiphospholipid antibody-positive autoimmune disease: a follow-up study,” American Journal of Perinatology, vol. 23, no. 4, pp. 247–251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Avčin, A. Ambrožič, M. Kuhar, T. Kveder, and B. Rozman, “Anticardiolipin and anti-β2 glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits,” Rheumatology, vol. 40, no. 5, pp. 565–573, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Ambrozic, “Anti-beta2-glycoprotein I antibodies in children with atopic dermatitis,” International Immunology, vol. 14, no. 7, pp. 823–830. View at Publisher · View at Google Scholar
  20. J. A. Girón-González, E. García Del Río, C. Rodríguez, J. Rodríguez-Martorell, and A. Serrano, “Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals,” Journal of Rheumatology, vol. 31, no. 8, pp. 1560–1567, 2004. View at Google Scholar · View at Scopus
  21. K. A. Breen, P. Seed, K. Parmar, G. W. Moore, S. E. Stuart-Smith, and B. J. Hunt, “Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome,” Thrombosis and Haemostasis, vol. 107, no. 3, pp. 423–429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Fischetti, P. Durigutto, V. Pellis et al., “Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor,” Blood, vol. 106, no. 7, pp. 2340–2346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Guerin, E. Casey, C. Feighery, and J. Jackson, “Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients,” Autoimmunity, vol. 31, no. 2, pp. 109–116, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Andreoli, C. Nalli, M. Motta et al., “Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?” Annals of the Rheumatic Diseases, vol. 70, no. 2, pp. 380–383, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. B. de Laat, R. H. W. M. Derksen, M. van Lummel, M. T. T. Pennings, and P. G. de Groot, “Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change,” Blood, vol. 107, no. 5, pp. 1916–1924, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Samarkos, K. A. Davies, C. Gordon, M. J. Walport, and S. Loizou, “IgG subclass distribution of antibodies against β2-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations,” Rheumatology, vol. 40, no. 9, pp. 1026–1032, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Arvieux, B. Roussel, D. Ponard, and M. G. Colomb, “IgG2 subclass restriction of anti-β2 glycoprotein 1 antibodies in autoimmune patients,” Clinical and Experimental Immunology, vol. 95, no. 2, pp. 310–315, 1994. View at Google Scholar · View at Scopus
  28. J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, and R. A. Dwek, “The impact of glycosylation on the biological function and structure of human immunoglobulins,” Annual Review of Immunology, vol. 25, pp. 21–50, 2007. View at Google Scholar
  29. Y. Kaneko, F. Nimmerjahn, and J. V. Ravetch, “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science, vol. 313, no. 5787, pp. 670–673, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. R. M. Anthony and F. Nimmerjahn, “The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo,” Current Opinion in Organ Transplantation, vol. 16, no. 1, pp. 7–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. R. M. Anthony and J. V. Ravetch, “A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs,” Journal of Clinical Immunology, vol. 30, no. 1, pp. S9–S14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Oku, T. Atsumi, M. Bohgaki et al., “Complement activation in patients with primary antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 1030–1035, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. H. P. McNeil, R. J. Simpson, C. N. Chesterman, and S. A. Krilis, “Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-Glycoprotein I (apolipoprotein H),” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 11, pp. 4120–4124, 1990. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Jefferis and D. S. Kumararatne, “Selective IgG subclass deficiency: quantification and clinical relevance,” Clinical and Experimental Immunology, vol. 81, no. 3, pp. 357–367, 1990. View at Google Scholar · View at Scopus
  35. P. H. Schur, F. Rosen, and M. E. Norman, “Immunoglobulin subclasses in normal children,” Pediatric Research, vol. 13, no. 3, pp. 181–183, 1979. View at Publisher · View at Google Scholar · View at Scopus
  36. M. A. H. French and G. Harrison, “Serum IgG subclass concentrations in healthy adults: a study using monoclonal antisera,” Clinical and Experimental Immunology, vol. 56, no. 2, pp. 473–475, 1984. View at Google Scholar · View at Scopus
  37. M. Odorczuk, L. B. Keil, and V. A. DeBari, “Binding of complement component C1q to anti-beta2 glycoprotein I antibodies from patients with antiphospholipid syndrome,” Inflammation Research, vol. 48, no. 10, pp. 524–526, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Truedsson, A. A. Bengtsson, and G. Sturfelt, “Complement deficiencies and systemic lupus erythematosus,” Autoimmunity, vol. 40, no. 8, pp. 560–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Aschermann, C. H. K. Lehmann, S. Mihai, G. Schett, D. Dudziak, and F. Nimmerjahn, “B cells are critical for autoimmune pathology in Scurfy mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 47, pp. 19042–19047, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Kaneko, F. Nimmerjahn, M. P. Madaio, and J. V. Ravetch, “Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors,” The Journal of Experimental Medicine, vol. 203, no. 3, pp. 789–797, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Sylvestre, R. Clynes, M. Ma, H. Warren, M. C. Carroll, and J. V. Ravetch, “Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice,” Journal of Experimental Medicine, vol. 184, no. 6, pp. 2385–2392, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. G. E. Ritchie, B. E. Moffatt, R. B. Sim, B. P. Morgan, R. A. Dwek, and P. M. Rudd, “Glycosylation and the complement system,” Chemical Reviews, vol. 102, no. 2, pp. 305–320, 2002. View at Publisher · View at Google Scholar
  43. Y. Palarasah, K. Skjodt, J. Brandt et al., “Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3,” Journal of Immunological Methods, vol. 362, no. 1-2, pp. 142–150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. D. G. Doherty, J. A. Underhill, P. T. Donaldson et al., “Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis,” Autoimmunity, vol. 18, no. 4, pp. 243–249, 1994. View at Publisher · View at Google Scholar · View at Scopus
  45. M.-H. Tao and S. L. Morrison, “Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region,” The Journal of Immunology, vol. 143, no. 8, pp. 2595–2601, 1989. View at Google Scholar · View at Scopus
  46. R. Jefferis, “Glycosylation of recombinant antibody therapeutics,” Biotechnology Progress, vol. 21, no. 1, pp. 11–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Mimura, S. Church, R. Ghirlando et al., “The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms,” Molecular Immunology, vol. 37, no. 12-13, pp. 697–706, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Huhn, M. H. J. Selman, L. R. Ruhaak, A. M. Deelder, and M. Wuhrer, “IgG glycosylation analysis,” Proteomics, vol. 9, no. 4, pp. 882–913, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Lund, N. Takahashi, J. D. Pound, M. Goodall, and R. Jefferis, “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” The Journal of Immunology, vol. 157, no. 11, pp. 4963–4969, 1996. View at Google Scholar · View at Scopus
  50. R. Forastiero, M. Martinuzzo, L. O. Carreras, and J. Maclouf, “Anti-β2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites,” Thrombosis and Haemostasis, vol. 79, no. 1, pp. 42–45, 1998. View at Google Scholar · View at Scopus
  51. J.-C. Reverter and D. Tàssies, “Mechanism of thrombosis in antiphospholipid syndrome: binding to platelets,” in Hughes Syndrome, M. A. Khamashta, Ed., pp. 403–414, Springer, London, UK, 2006. View at Google Scholar
  52. G. Espinosa, R. Cervera, J. Font, and Y. Shoenfeld, “Antiphospholipid syndrome: pathogenic mechanisms,” Autoimmunity Reviews, vol. 2, no. 2, pp. 86–93, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Shi, B. Giannakopoulos, X. Yan et al., “Anti-β2-glycoprotein I antibodies in complex with β2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V,” Arthritis & Rheumatism, vol. 54, no. 8, pp. 2558–2567, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. P. L. Meroni, E. Raschi, M. Camera et al., “Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome,” Journal of Autoimmunity, vol. 15, no. 2, pp. 237–240, 2000. View at Publisher · View at Google Scholar · View at Scopus